Loading institutional data...
Loading institutional data...
Held by 571 of 5,944 reporting institutions (97th percentile) — extremely crowded.
Data as of Q1 2026
Loading snapshot...
Loading financials...
Loading valuation...
Loading quality & risk...
Loading dividends & returns...
Loading capital allocation...
Loading debt & leverage...
Loading performance...
Loading peer comparison...
Loading ownership map...
Loading crowding analysis...
Loading conviction analysis...
Loading buy/sell flow...
Loading ownership trends...
Loading top holders...
Loading top holders...
Total shares institutions bought (green) vs sold (red) each quarter across all holders.
Inferred from quarter-over-quarter change in each fund's 13F position (new stakes count as buys, exits as sells). Not tick-level trades.
Solve the discounted cash flow backwards, then stress-test the assumptions.
To be worth $74.16 today, the market must believe free cash flow compounds 10.5%/yr for a decade (off $386M normalized FCF).
The market's 10.5% is more conservative than its 9-yr track record.
2-stage DCF · 0.14B shares · net debt -$526M
mean 32.1% · volatility σ 56% · implied rate exceeded in 6/9 yrs
Central path = implied 10.5%/yr growth; shaded band = ±1σ (56%) of this company's historical FCF volatility, widening with time. The wider the band, the less certain the growth.
Reverse DCF: rather than guessing a fair value, we solve for the growth the current price implies, then you stress-test the assumptions. Enterprise value of the FCF stream, less net debt, ÷ shares. Educational — not a recommendation.
Is the value real, and is the business safe? Academic scores + earnings quality + solvency, from SEC filings.
8/8 of the 9 checks — 1 couldn't be scored (see above), so the score is out of the 8 with data.
Safe > 2.99 · grey 1.81–2.99 · distress < 1.81
Eight indices comparing this year to last (receivables, margins, asset quality, growth, accruals, leverage). Above −1.78 suggests possible manipulation; below −2.22 is clean.
A screen, not proof — high growth alone can raise it.
Earnings are backed by cash (FCF ≥ net income) — high quality. Lower/negative accruals = higher quality (Sloan).
Coverage data unavailable.
F-Score (0–9 fundamental momentum), Altman Z (distress risk), and Beneish M (earnings-manipulation screen) are academic models computed from the SEC filings. Screens and context — educational, not recommendations.
What the company returns to shareholders — and whether it's covered by cash.
No dividend to cover. Last year: $0 dividends + $300M buybacks = $300M returned on $589M FCF.
Yields use the latest fiscal-year dividends/buybacks over current market cap. Dividends and buybacks from the SEC cash-flow statement; payout coverage vs net income and free cash flow. Educational — not a recommendation.
How management deployed cash over 10 years — and what it earned on reinvestment.
A reinvestment story — most cash went back into growth rather than to shareholders.
Reinvestment has been productive — operating income grew well per dollar put in. Current ROIC on all capital: 12%. Rough measure (includes maintenance capex).
Cash uses aggregated from the SEC cash-flow statement over 10 fiscal years. "Return on reinvestment" is a rough proxy — operating-income change ÷ cumulative CapEx + M&A — and includes maintenance capex. Educational — not a recommendation.
How much the company owes, how it's trended, and how comfortably it's serviced.
Insufficient EBITDA/debt history.
Green ≤ 1.5× · amber ≤ 3× · red > 3× (leverage relative to cash earnings).
Interest expense isn't separately reported — often netted into “other income (expense), net.”
Cash vs short-term debt unavailable.
Short-term / long-term split not separately reported.
Debt, cash, interest and equity from the SEC balance sheet & income statement. Effective rate = interest ÷ average debt. Educational — not a recommendation.
EOD close · as of 2026-09-17
How a revenue dollar becomes profit — FY2025
Each value shows its share of revenue below it (common-size).
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $2.94B 100.0% | $2.52B 100.0% | $1.57B 100.0% | $1.02B 100.0% | $958.1M 100.0% | $789.0M 100.0% | $785.4M 100.0% | $713.0M 100.0% | $636.0M 100.0% | $564.0M 100.0% |
| Cost of Revenue | $957.8M 32.6% | $1.04B 41.1% | $548.2M 34.9% | $263.7M 25.8% | $239.2M 25.0% | $217.5M 27.6% | $180.0M 22.9% | $159.4M 22.4% | $150.5M 23.7% | $134.7M 23.9% |
| Cost of Products | — | — | — | — | — | — | — | — | $150.5M 23.7% | $134.7M 23.9% |
| Gross Profit | — | — | $1.02B 65.1% | $759.1M 74.2% | $718.9M 75.0% | $571.6M 72.4% | $605.4M 77.1% | $553.6M 77.6% | $485.5M 76.3% | $429.3M 76.1% |
| Research & Development | $147.2M 5.0% | $163.8M 6.5% | $124.0M 7.9% | $73.0M 7.1% | $97.3M 10.2% | $84.5M 10.7% | $60.1M 7.6% | $55.5M 7.8% | $43.7M 6.9% | $44.5M 7.9% |
| Selling, General & Admin | $1.18B 40.1% | $981.4M 39.0% | $643.8M 41.0% | $432.1M 42.2% | $408.1M 42.6% | $354.8M 45.0% | $354.8M 45.2% | $311.6M 43.7% | $267.8M 42.1% | $222.2M 39.4% |
| Total Operating Expenses | — | — | $887.2M 56.6% | $531.2M 51.9% | $546.9M 57.1% | $460.1M 58.3% | $433.4M 55.2% | $384.2M 53.9% | $323.7M 50.9% | $275.1M 48.8% |
| Operating Income | $479.8M 16.3% | $166.0M 6.6% | $133.1M 8.5% | $228.0M 22.3% | $172.0M 17.9% | $111.4M 14.1% | $172.0M 21.9% | $169.3M 23.7% | $161.8M 25.4% | $154.1M 27.3% |
| Other Income (Expense), net | $125.3M 4.3% | -$45.3M -1.8% | $32.3M 2.1% | $15.1M 1.5% | $8.5M 0.9% | $14.5M 1.8% | $18.0M 2.3% | $19.3M 2.7% | $8.1M 1.3% | $3.1M 0.6% |
| Pretax Income | $605.1M 20.6% | $120.7M 4.8% | $165.4M 10.5% | $243.0M 23.8% | $180.4M 18.8% | $125.9M 16.0% | $189.9M 24.2% | $188.6M 26.5% | $169.9M 26.7% | $157.3M 27.9% |
| Income Tax Expense | $67.2M 2.3% | $17.7M 0.7% | $42.5M 2.7% | $52.9M 5.2% | $31.2M 3.3% | $23.6M 3.0% | $34.7M 4.4% | $32.1M 4.5% | $62.6M 9.8% | $52.9M 9.4% |
| Net Income | $537.9M 18.3% | $103.0M 4.1% | $122.9M 7.8% | $190.2M 18.6% | $149.2M 15.6% | $102.3M 13.0% | $155.2M 19.8% | $156.5M 21.9% | $107.3M 16.9% | $104.3M 18.5% |
| Per Share | ||||||||||
| EPS (Basic) | $3.98 | $0.76 | $1.09 | $1.89 | $1.48 | $1.04 | $1.57 | $1.60 | $1.12 | $1.09 |
| EPS (Diluted) | $3.92 | $0.75 | $1.07 | $1.85 | $1.44 | $1.01 | $1.52 | $1.54 | $1.10 | $1.08 |
| Weighted Avg Shares (Basic) | 135.2M | 135.7M | 113.1M | 100.5M | 100.7M | 98.6M | 99.2M | 97.9M | 96.2M | 95.6M |
| Weighted Avg Shares (Diluted) | 137.1M | 137.9M | 114.6M | 102.6M | 103.6M | 101.0M | 102.0M | 101.3M | 97.9M | 96.4M |
Source: SEC EDGAR XBRL filings (annual, fiscal year). Quarterly flow items are derived from cumulative filings; balance-sheet figures are as-of each period end. Ratios and margins are computed, not reported.
Top 40 institutional holders — bubble size is position value, color is the move since last quarter. Hover any holder for detail.
Drag any bubble to rearrange · size = dollar value of the position
Ranked against 1085 sector peers with collected financials. Valuation from latest close × latest fiscal-year fundamentals; 13F conviction as of 2026-03-31.
Percentile is “goodness” within the peer set (100 = best). For valuation and leverage that means cheaper / less-levered ranks higher.
| Company | Mkt cap ▼ | P/E | EV/EBITDA | P/S | Rev gr | Gross | Net | ROE | ROIC | Net D/EBITDA | 13F |
|---|---|---|---|---|---|---|---|---|---|---|---|
| BCAX | $1.20T | — | — | — | — | — | — | -34.4% | -34.4% | — | 143 |
| LLY | $1.02T | 49.6× | — | 15.7× | 44.7% | 83.0% | 31.7% | 77.8% | 29.9% | — | 4,193 |
| AKTX | $916.2B | — | — | — | — | — | — | -61.1% | -61.1% | — | 1 |
| JNJ | $643.4B | 24.2× | — | 6.8× | 6.0% | 67.9% | 28.5% | 32.9% | 20.7% | — | 4,451 |
| ABBV | $464.4B | 111.2× | 33.2× | 7.6× | 8.6% | 70.2% | 6.9% | -129% | 6.6% | 4.2× | 3,895 |
| MRK | $362.6B | 19.9× | — | 5.6× | 1.3% | 74.8% | 28.1% | 34.7% | 17.9% | — | 3,594 |
| UNH | $340.0B | 28.4× | 19.7× | 0.8× | 11.8% | 88.7% | 2.7% | 12.0% | 6.8% | 3.9× | 2,891 |
| AZN | $252.6B | — | — | — | — | — | — | — | — | — | 1,248 |
| TMO | $244.5B | 36.5× | 31.5× | 5.5× | 3.9% | — | 15.0% | 12.6% | 7.0% | 4.9× | 2,481 |
| AMGN | $202.8B | 26.4× | 17.4× | 5.5× | 10.0% | 67.2% | 21.0% | 89.1% | 12.2% | 3.8× | 3,014 |
| GILD | $183.3B | 21.8× | 20.0× | 6.2× | 2.4% | 78.8% | 28.9% | 37.5% | 17.9% | 2.4× | 2,218 |
| ABT | $178.2B | 27.5× | 19.3× | 4.0× | 5.7% | 56.4% | 14.7% | 12.5% | 10.0% | 1.4× | 2,964 |
| PFE | $156.1B | 20.2× | — | 2.5× | -1.6% | 74.3% | 12.4% | 9.0% | 5.1% | — | 2,838 |
| DHR | $147.3B | 41.3× | 30.5× | 6.0× | 2.9% | 59.1% | 14.7% | 6.9% | 5.1% | 3.4× | 2,083 |
| ISRG | $135.8B | 48.6× | 37.3× | 13.5× | 20.5% | 66.0% | 28.4% | 16.0% | 16.0% | — | 2,190 |
| VRTX | $130.4B | 33.5× | 28.6× | 10.9× | 8.9% | 86.2% | 32.9% | 21.2% | 21.2% | — | 1,609 |
| BMY | $129.4B | 18.4× | — | 2.7× | -0.2% | 71.1% | 14.6% | 38.2% | 11.1% | — | 2,431 |
| MDT | $118.5B | 24.8× | 12.6× | 3.3× | 8.4% | 65.0% | 13.2% | 9.7% | 9.4% | 0.2× | 2,114 |
| LGVN | $117.4B | — | — | 97924.4× | -49.9% | 67.0% | -1894% | -400% | -400% | — | 31 |
| CVS | $116.6B | 66.0× | 11.7× | 0.3× | 7.8% | 45.0% | 0.4% | 2.4% | 2.4% | 0.0× | 1,795 |
| SYK | $108.8B | 33.9× | 18.7× | 4.3× | 11.2% | 64.0% | 12.9% | 14.5% | 8.5% | 2.5× | 2,196 |
| MCK | $103.4B | 23.1× | 16.3× | 0.3× | 12.4% | 3.6% | 1.2% | -219% | 109% | 1.0× | 1,946 |
| HCA | $96.7B | 15.2× | — | 1.3× | 7.1% | — | 9.0% | -113% | 16.8% | — | 1,346 |
| ELV | $91.1B | 16.4× | 15.4× | 0.5× | 12.5% | 89.4% | 2.8% | 12.9% | 7.6% | 4.2× | 1,397 |
| REGN | $81.0B | 18.7× | 19.4× | 5.7× | 1.0% | — | 31.4% | 14.4% | 13.6% | 0.5× | 1,336 |
| GMED | $10.2B | 19.2× | 12.8× | 3.5× | 16.7% | 67.4% | 18.3% | 11.8% | 11.8% | — | 571 |
Peers = companies sharing GMED's sector (Healthcare) with collected SEC financials. Multiples use the most recent end-of-day close and latest fiscal-year fundamentals (trailing, not forward). Missing cells mean the peer never reported that line item, has no collected price, or has a non-positive denominator. Not investment advice.
Total return (dividends reinvested) vs the market, from quarter-end prices.
Above 0 = ahead of the S&P 500 since the window start; below 0 = behind. Rising means it's pulling ahead.
How far the stock fell below its prior peak. Deeper, longer drawdowns = a rougher ride to the same return.
Quarter-end, dividend-adjusted (total return). Beta & volatility from quarterly returns (annualized). Benchmark is the S&P 500 (SPY total return). Annual returns compound the quarters ending in each calendar year; the first and last years in a window may be partial. Past performance doesn't predict future results.
EOD close · as of 2026-09-17
No material risks flagged.
Where each multiple sits in its own 14-yr range · 9th pct blended
Dot = today · shaded = middle 50% · line = median. Lower percentile = cheaper vs its own 14-yr history.
Is the profit real, and how strong is the balance sheet?
FY2025 · every deduction from revenue to net income
DuPont — the three levers
Returns are margin-driven, not leverage-driven — higher quality.
What the company owes vs. what it holds
Year-by-year maturities aren't in SEC companyfacts (footnote-only), so this shows the debt/cash structure and net leverage instead.
Latest year: profit growth vs revenue growth
High operating leverage: profit moved 11.4× as fast as sales — great in an upturn, painful in a downturn.
Each line as % of revenue — the trend in color
| % of revenue | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Cost of Revenue | 22.4 | 22.9 | 27.6 | 25.0 | 25.8 | 34.9 | 41.1 | 32.6 |
| Gross Profit | 77.6 | 77.1 | 72.4 | 75.0 | 74.2 | 65.1 | — | — |
| R&D | 7.8 | 7.6 | 10.7 | 10.2 | 7.1 | 7.9 | 6.5 | 5.0 |
| SG&A | 43.7 | 45.2 | 45.0 | 42.6 | 42.2 | 41.0 | 39.0 | 40.1 |
| Operating Income | 23.7 | 21.9 | 14.1 | 17.9 | 22.3 | 8.5 | 6.6 | 16.3 |
| Income Tax | 4.5 | 4.4 | 3.0 | 3.3 | 5.2 | 2.7 | 0.7 | 2.3 |
| Net Income | 21.9 | 19.8 | 13.0 | 15.6 | 18.6 | 7.8 | 4.1 | 18.3 |
Green = margin-favorable vs the row's own range · red = unfavorable.
The metrics that matter, over time
A 30-second read on GMED: price, valuation, headline fundamentals, and an auto-generated scorecard from SEC filings. Flags are rule-based signals, not recommendations.